Home / current
Trials
Treatment Guidelines
PENTA Network
Training
Key publications
All publications
Other activities
Contacts
Risk calculator
Links
Area for PENTA network members (password
needed)
New collaborations
PENTA-LABNET has been funded by the European Commission to set up and link a pan-European network of Pharmacology, Virology and Immunology laboratories working on paediatric ARV treatment that will use common standards to undertake priority research studies. This network will serve as the platform for a number of coordinating activities to ensure that studies undertaken are coordinated and together facilitate the development and early use of novel and improved paediatric ARV drugs for treating HIV infected children.
PENTA together with the CASCADE, Eurosida and EuropeHIVResistance groups has received funding from the European Commission for the ACTIVATE project which will provide capacity building and training for health care workers.
PENTA is also a partner in the NEAT network of excellence; this will help establish a clinical and laboratory network for enrolling adolescents in clinical trials.
PENTA is one of the partners in TEDDY www.teddynoe.org, which aims to promote the availability of safe and effective medicines for children in Europe by integrating existing expertise and good practices, as well as stimulating further developments.
Withdrawal of PCP prophylaxis
Some PENTA clinical centres conducted a retrospective analysis of withdrawal of PCP prophylaxis. The analysis has been published in AIDS:
Urschel S, Ramos J, Mellado M, Giaquinto C, Verweel G,
Schuster T, Niehues T, Belohradsky B, Wintergerst U; the European PCP-withdrawal
Study Group. Withdrawal of Pneumocystis jirovecii prophylaxis in HIV-infected
children under highly active antiretroviral therapy. AIDS. 2005
Dec 2;19(18):2103-2108. (Reference)
HPPMCS Collaboration
PENTA has contributed data to The HIV Paediatric Prognostic Markers Collaborative Study (HPPMCS), an individual-patient-data meta-analysis to investigate the "natural history" of HIV-1 RNA and CD4+ cell count in perinatally HIV-infected children. This was a collaboration of investigators of European and American cohort studies and randomised trials of ART or immune therapies in HIV-infected children and has data on more than 5000 children exposed to either no treatment or zidovudine monotherapy only. This study has developed a risk calculator which gives estimates of the short-term risks of progression to AIDS and death in the absence of therapy.
UK - Medicines for Children Research Network (MCRN)
PENTA 11, PENTA 15 and PENPACT 1 have been adopted by the UK Medicines for Children Research Network. The MCRN website (www.mcrn.org.uk) gives information on the local research networks and the training courses now available.